Form 4: Guardant Health Co-CEO Sells Over 119,000 Shares Under Pre-Arranged Trading Plan

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, sold 119,284 shares of common stock for approximately $5.97 million in early June 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), sold a total of 119,284 shares of the company's common stock across three transactions in June 2025.
• The sales occurred on June 5, 2025, with 1,680 shares sold at a weighted average price of $50.0041 per share.
• An additional 39,751 shares were sold on June 6, 2025, at a weighted average price of $50.0722 per share.
• The final reported sale was on June 9, 2025, involving 77,853 shares at a weighted average price of $50.0936 per share.
• The total proceeds from these sales amount to approximately $5.97 million.
• Following these transactions, Mr. Talasaz beneficially owns 2,069,456 shares of Guardant Health common stock.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Talasaz on December 17, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It represents a planned liquidity event for the executive rather than a reaction to adverse company news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on immediate, non-public information, thereby reducing concerns about opportunistic insider selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Risks

• While the sales were pre-planned, a significant reduction in an executive's direct ownership could potentially be viewed by some investors as a signal, though this is largely mitigated by the transparency and pre-scheduled nature of a 10b5-1 plan.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends for the biotechnology or healthcare sectors. It is specific to the personal stock management of a Guardant Health executive.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, which could be interpreted differently depending on individual investment philosophies, though the 10b5-1 plan context is important for understanding the nature of the sale.

Key Dates

Keywords

Guardant Health, GH, AmirAli Talasaz, Insider Trading, Form 4, Stock Sale, Rule 10b5-1, Executive Compensation, Biotechnology, Healthcare